Saturday 17 October 2026
Export ACRV’s income statement to Excel — free account
Acrivon Therapeutics, Inc.
ACRV Healthcare Biotechnology
In the quarter to June 2026, EPS grew 21.8% and free cash flow grew 12.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.64
0.12
−6.82%
Follow ACRV
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 10.90 | 3.41 | 3.19 | 1.05 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | 20.70 | 25.47 | 11.90 | 8.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 42 | 44 | 61 | 78 | 76 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | — | — | (5) | (16) | (31) | (60) | (81) | (78) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | (5) | (16) | (31) | (60) | (81) | (78) | |||||
| Depreciation | — | — | — | — | 0 | 0 | 0 | (3) | (3) | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | (3.70) | (9.32) | (7.56) | (2.74) | (2.38) | (2.02) | |||||
| Cash flow | — | — | — | — | (1.96) | (8.02) | (7.31) | (1.93) | (1.94) | (1.65) | |||||
| Capex | — | — | — | — | (0.01) | (0.14) | (0.53) | (0.06) | (0.08) | (0.04) | |||||
| Free cash flow | — | — | — | — | (1.97) | (8.16) | (7.83) | (1.99) | (2.03) | (1.70) | |||||
| Book value | — | — | — | — | 0.88 | 56.62 | 41.36 | 5.49 | 5.23 | 2.92 | |||||
| Shares, m | — | — | — | — | 1 | 2 | 4 | 22 | 34 | 39 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (3) | (14) | (30) | (43) | (66) | (64) | ||||
| Capex | — | — | — | — | 0 | 0 | (2) | (1) | (3) | (2) | |||||
| Free cash flow | — | — | — | — | (3) | (14) | (32) | (44) | (68) | (65) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 1 | 97 | 126 | 116 | 164 | 105 | ||||
| Total debt | — | — | — | — | 10 | 128 | 5 | — | — | — | |||||
| Net debt | — | — | — | — | (2) | (100) | (128) | (127) | (179) | (119) | |||||
| Shareholders’ equity | — | — | — | — | 1 | 99 | 170 | 121 | 177 | 113 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (29.87) | (21.66) | (37.80) | (48.11) | (47.75) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | (47.77) | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | 0.00 | 100.82 | (42.50) | (41.41) | (54.07) | (53.86) | |||||
Negative figures in brackets.
Charts ten years each
Acrivon Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PMN Promis Neurosciences | $78.0M | — (loss-making) | — | 0.00% | n/m | −169.46% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PTHS Pelthos Therapeutics Inc. | $77.6M | — (loss-making) | — (loss-making) | — | n/m | −1,614.99% (below 0%: shrinking) | 76.86% | (111.02%) | Compare |
| TELO Telomir Pharmaceuticals, Inc. | $77.3M | — (loss-making) | — | — | n/m | −45.34% (below 0%: shrinking) | — | 0.00% | Compare |
| NTRB Nutriband Inc. | $76.2M | — (loss-making) | 4.6× | −29.72% (below 0%: shrinking) | n/m | +55.46% (above 0%: growing) | 41.58% | (203.57%) | Compare |
| CRDF Cardiff Oncology, Inc. | $75.5M | — (loss-making) | — (loss-making) | −14.05% (below 0%: shrinking) | n/m | −41.36% (below 0%: shrinking) | 100.00% | (9,245.19%) | Compare |
| ACRV Acrivon Therapeutics, Inc. | $75.4M | — (loss-making) | — | — | n/m | +12.59% (above 0%: growing) | 0.00% | 0.00% | |
| OKYO OKYO Pharma Limited Sponsored ADR | $75.1M | — (loss-making) | — | — | n/m | +37.39% (above 0%: growing) | 0.00% | — | Compare |
| PDSB PDS Biotechnology Corporation | $72.8M | — (loss-making) | — | — | n/m | +69.32% (above 0%: growing) | 0.00% | 0.00% | Compare |
| HRTX Heron Therapeutics, Inc. | $71.5M | — (loss-making) | — (loss-making) | +1.25% (above 0%: growing) | n/m | +78.75% (above 0%: growing) | 69.28% | (5.43%) | Compare |
| Median of peers | $75.9M | — | — | −7.02% | — | −1.99% | 41.58% | (5.43%) |
Acrivon Therapeutics, Inc. (ACRV) key facts
- Acrivon Therapeutics, Inc. (ACRV) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ACRV traded at $1.64, a market capitalization of $75.4 million.
- Return on equity was −53.9% and debt-to-equity 0.00.